ReviewFrontiers in immunology2025
Development of human mycoplasma vaccines: navigating the IL-17A paradox.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite decades of effort, effective vaccines against pathogenic human mycoplasmas remain elusive, largely due to vaccine-enhanced disease (VED). Recent discoveries highlight the paradoxical role of interleukin-17A (IL-17A) as both protector and instigator of pathology. Although IL-17A is indispensable for mucosal defense against many pathogens, its dysregulated expression following mycoplasma vaccination can provoke excessive neutrophilic inflammation and exacerbate pulmonary injury. This review synthesizes emerging evidence implicating bacterial lipoproteins as key triggers of maladaptive IL-17A responses. We delineate the duality of IL-17A in mycoplasma infections, mediating both protection and tissue damage, and critically examine its implications for vaccine design. Integrating insights from recent animal models, B-cell depletion studies, and proteomic analyses, we propose a framework for next-generation vaccines that elicit protective immunity while circumventing IL-17A-driven immunopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.